Moderna's experimental cancer vaccine, used alongside one of Merck’s drugs, has shown promising results in cutting the risk of death or relapse of severe skin cancer by nearly half. The vaccine, developed by Merck and Moderna, in combination with Keytruda, has demonstrated a delay in the return of deadly skin cancer for three years. The CEO of Moderna, Stéphane Bancel, highlighted the positive trial data and mentioned that the vaccine could potentially launch as early as 2025. The news has caused a surge in Moderna's stock price, with a notable 11.1% increase in pre-market trading. The positive results provide a welcome distraction for Moderna from the challenges faced in Covid-19 shot sales.
Moderna: good news on skin cancer vaccine is welcome distraction from Covid-19 shot sales woes $MRNA https://t.co/XYYsaBMZgq
Moderna: good news on skin cancer vaccine is welcome distraction from Covid-19 shot sales woes https://t.co/mLX7kvIY1U | opinion
Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says https://t.co/4M7voWZu8T
$MRNA | Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted' https://t.co/9242tYu3Ky
Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says https://t.co/4M7voWZu8T
Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says https://t.co/NypSFv4j9n
$MRNA's experimental cancer vaccine used alongside one of Merck’s blockbuster drugs cut the risk of death or relapse of the most deadly form of skin cancer by nearly half. CEO Stéphane Bancel joins to discuss: https://t.co/jVomGh2aKS
Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years https://t.co/SdaBLjq5FH https://t.co/qJwQqCY5jH
$MRNA (+11.1% pre) Moderna, $MRK Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says - CNBC https://t.co/Cl7hzbaUpx
Moderna surges on positive skin-cancer-vaccine trial data https://t.co/JjwsOKbaac
$MRNA 🔸MODERNA CANCER VACCINE COULD LAUNCH AS EARLY AS 2025: CEO
A personalized vaccine developed by Merck and Moderna helped prevent the recurrence of severe skin cancer for three years, in promising new results from a study https://t.co/jVYbDmkbsC